Immunodominant Mycobacterium tuberculosis Protein Rv1507A Elicits Th1 Response and Modulates Host Macrophage Effector Functions
( ) persists as latent infection in nearly a quarter of the global population and remains the leading cause of death among infectious diseases. While BCG is the only vaccine for TB, its inability to provide complete protection makes it imperative to engineer BCG such that it expresses immunodominant...
Saved in:
Published in | Frontiers in immunology Vol. 11; p. 1199 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
21.07.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | (
) persists as latent infection in nearly a quarter of the global population and remains the leading cause of death among infectious diseases. While BCG is the only vaccine for TB, its inability to provide complete protection makes it imperative to engineer BCG such that it expresses immunodominant antigens that can enhance its protective potential.
comparative genomic analysis of Mycobacterium species identified
Rv1507A as a "signature protein" found exclusively in
.
(cell lines) and
experiments carried out in mice, using purified recombinant Rv1507A revealed it to be a pro-inflammatory molecule, eliciting significantly high levels of IL-6, TNF-α, and IL-12. There was increased expression of activation markers CD69, CD80, CD86, antigen presentation molecules (MHC I/MHCII), and associated Th1 type of immune response. Rv1507A knocked-in
also induced significantly higher pro-inflammatory Th1 response and higher survivability under stress conditions, both
(macrophage RAW264.7 cells) and
(mice). Sera derived from human TB patients showed significantly enhanced B-cell response against
Rv1507A. The ability of
Rv1507A to induce immuno-modulatory effect, B cell response, and significant memory response, renders it a putative vaccine candidate that demands further exploration. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology Edited by: Mario Alberto Flores-Valdez, CONACYT Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco (CIATEJ), Mexico These authors have contributed equally to this work Reviewed by: Maria E. Sarmiento, Universiti Sains Malaysia Health Campus, Malaysia; Arshad Khan, McGovern Medical School, University of Texas Health Science Center at Houston, United States Present address: Javeed Ahmad, Molecular Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, United States |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2020.01199 |